LACTOLOGY FOUNDATION

A07AX01 corresponds to broxyquinoline, a halogenated hydroxyquinoline classified as an “other intestinal antiinfective” used mainly for infectious diarrhoea and protozoal intestinal infections. From a toxicological‑lactological perspective, its historical association with neurotoxicity and limited modern lactation data mean that use in breastfeeding requires caution, with preference for safer alternatives where available.atcddd.fhi+4

ATC classification and substance identity

Broxyquinoline is assigned the ATC code A07AX01 within group A07 “Antidiarrheals, intestinal anti‑inflammatory/anti‑infective agents” and subgroup A07A “Intestinal antiinfectives”.atcddd.fhi+1
A07AX denotes “Other intestinal antiinfectives”, a residual subgroup for agents not fitting into antibiotics (A07AA), sulfonamides (A07AB) or imidazole derivatives (A07AC).atcddd.fhi+1

Chemically, broxyquinoline is a halogenated quinoline (organobromide, 8‑hydroxyquinoline derivative) with antiprotozoal and antimicrobial properties.pubchem.ncbi.nlm.nih+2
It has been marketed under trade names such as Intestopan and Broxine, mainly for gastrointestinal infections and diarrhoeal disorders.sciencedirect+1

Pharmacodynamic properties

Broxyquinoline exhibits broad‑spectrum antimicrobial activity against certain bacteria and protozoa involved in intestinal infections.synapse.patsnap+1
Its mechanisms include chelation of essential metal ions used in microbial metabolism, disruption of cell membrane integrity and permeability, and interference with microbial genetic material replication.journals.asm+2

These combined actions lead to inhibition of growth and death of susceptible pathogens in the gastrointestinal tract.synapse.patsnap+1
Some sources also describe modest anti‑inflammatory effects that may contribute to symptom relief in diarrhoeal and certain dermatological conditions.sciencedirect+1

Therapeutic indications and clinical use

Historically, broxyquinoline was used as prophylaxis and treatment for infectious diarrhoea and amoebiasis, as well as for certain gastrointestinal infections.sciencedirect+1
Clinical trials and experience have indicated potential efficacy in managing gastrointestinal infections and amoebic disease, although modern practice frequently favours better‑characterised agents.sciencedirect+1

The drug has also been used in some topical formulations for skin conditions, but A07AX01 specifically denotes intestinal use as an oral antiinfective.pubchem.ncbi.nlm.nih+1
Current utilisation is more limited and often restricted, reflecting evolving standards of care and safety concerns for halogenated hydroxyquinolines.sciencedirect+1

Dosage, DDD and administration

ATC/DDD lists broxyquinoline under A07AX01 but does not consistently assign a Defined Daily Dose (DDD) value, indicating limited or variable utilisation information.atcddd.fhi+1
Clinical dosing regimens for oral broxyquinoline commonly involve one tablet two to three times daily with meals, over a short treatment course tailored to infection severity and patient status.synapse.patsnap

Oral tablets are the main intestinal formulation, designed to act locally in the gut, with food intake recommended to improve tolerance and absorption.synapse.patsnap
Topical preparations (for skin) exist but fall under different codes and are not the focus of A07AX01 intestinal classification.synapse.patsnap+1

Pharmacokinetics and systemic exposure

Broxyquinoline is intended as a locally acting intestinal antiinfective, but halogenated quinoline derivatives can be systemically absorbed to variable degrees.pubchem.ncbi.nlm.nih+1
Systemic exposure depends on dose, duration, mucosal integrity and individual pharmacokinetics, and prolonged or high‑dose use can lead to tissue accumulation.sciencedirect+1

The compound has been associated with peripheral neuropathy and other neurotoxic manifestations after long‑term therapy, suggesting relevant distribution to nervous tissue.sciencedirect+1
Available data do not provide detailed breast milk pharmacokinetics, but potential systemic absorption in the mother implies that some passage into milk cannot be excluded.pmc.ncbi.nlm.nih+1

Toxicological profile in adults

Common adverse effects of broxyquinoline include gastrointestinal disturbances such as nausea, vomiting and diarrhoea, along with occasional allergic reactions (rash, pruritus, swelling).synapse.patsnap+1
Serious allergic reactions (e.g., severe dizziness, breathing difficulty) have been reported, consistent with hypersensitivity to hydroxyquinoline compounds.synapse.patsnap+1

Long‑term use may cause peripheral neuropathy, presenting as tingling, numbness or pain in the extremities, and other neurotoxic effects have historically been described for related compounds.sciencedirect+1
Contraindications include known hypersensitivity to hydroxyquinoline derivatives or any component of the formulation; caution is advised in neurological disease or when prolonged therapy is contemplated.sciencedirect+1

Lactational safety and infant risk

General lactation guidance notes that most medicines appear in breast milk at less than 10% of the maternal dose, and many are compatible with breastfeeding, but drugs with inherent toxicity or high infant exposure can be contraindicated.pmc.ncbi.nlm.nih+1
Broxyquinoline belongs to a class with recognised neurotoxicity risk on prolonged exposure, and specific lactation data are limited, so the infant risk is difficult to quantify but cannot be considered negligible.sciencedirect+1

Because halogenated hydroxyquinolines may accumulate and affect the nervous system, theoretical concerns arise about neurotoxic effects in breastfed infants if meaningful maternal systemic exposure occurs.sciencedirect+1
Given the absence of reassuring pharmacokinetic and clinical data in lactation, broxyquinoline should not be regarded as a first‑line option in breastfeeding women, especially for non‑severe infections where safer alternatives exist.pmc.ncbi.nlm.nih+1

Clinical recommendations for breastfeeding women

Modern lactation references advise that most common antibiotics and many locally acting agents can be safely used in breastfeeding when prescribed at the lowest effective dose and shortest duration.pmc.ncbi.nlm.nih+1
In the context of intestinal infection in a breastfeeding woman, preference should be given to established lactation‑compatible antibiotics (e.g., many beta‑lactams, macrolides) or better‑characterised agents rather than broxyquinoline.medsafe+2

If broxyquinoline A07AX01 is considered absolutely necessary (e.g., lack of alternatives, specific pathogen sensitivity), an individualised risk–benefit assessment is essential, including the severity of maternal disease and the infant’s age and health.who+1
Depending on circumstances, options may include avoiding use, limiting treatment duration, or, in high‑risk scenarios, temporary interruption of breastfeeding with appropriate support measures.who+1

Breastfed infants should be monitored for gastrointestinal symptoms, irritability or unusual neurological signs; any concerning findings warrant prompt review of maternal therapy and lactation management.pmc.ncbi.nlm.nih+1
As a general principle, broxyquinoline should be used cautiously in lactation and only when benefits clearly outweigh potential risks, with documentation of clinical reasoning.pmc.ncbi.nlm.nih+1

Educational summary for practice

A07AX01 broxyquinoline is a halogenated hydroxyquinoline intestinal antiinfective used historically for infectious diarrhoea and amoebiasis, acting via metal ion chelation, membrane disruption and antimicrobial activity in the gut.sciencedirect+2
Its neurotoxicity potential with prolonged use and lack of robust lactation data make it a relatively high‑concern drug in breastfeeding compared with many alternative antiinfectives.sciencedirect+1

In toxicological‑lactological practice, broxyquinoline is best approached as a non‑preferred option in lactating women; safer, well‑characterised antibiotics and intestinal antiinfectives should usually be chosen instead.pmc.ncbi.nlm.nih+2
When broxyquinoline use is unavoidable, careful risk–benefit assessment, short treatment duration, and close monitoring of both mother and infant are key components of safe clinical management.who+1